Relapse Assessment for Schizophrenia Patients (RASP)

Otsuka Pharmaceutical Development & Commercialization, Inc (USA)

Distributed by Mapi Research Trust


Distributed by Mapi Research Trust

Basic description

Developed in 2016


Otsuka Pharmaceutical Development & Commercialization, Inc (USA)

RASP © Otsuka Pharmaceutical Development & Commercialization, Inc. 2016, All Rights Reserved.
To identify changes in patient with Schizophrenia symptomology or functional status in order to assess the relapse risk
Therapeutic area
  • Mental Disorders
Therapeutic indication


Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Velligan D, Carpenter W, Waters HC, Gerlanc NM, Legacy SN, Ruetsch C. Relapse Risk Assessment for Schizophrenia Patients (RASP): a New Self-Report Screening Tool. Clin Schizophr Relat Psychoses. 2017 Nov 22. (PubMed abstract)

Velligan D, Ruetsch C, Legacy S, Waters H, Gerlanc N, Carpenter W. Psychometric Evaluation of a New Relapse Risk Screener for Patients With Schizophrenia. US Psychiatric and Mental Health Congress, 2016

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use


Otsuka Pharmaceutical Development & Commercialization, Inc (USA)

Otsuka Pharmaceutical Development & Commercialization, Inc.
2440 Research Boulevard
Rockville, MD 20850
Phone: +1-240-683-3517 |
Fax: +1-301-721-7517 |

Contact person:
Dorothee Oberdhan, MS
Senior Manager, HEOR and Outcomes Management

Contact information

Mapi Research Trust
27 rue de la Villette
69003 Lyon
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access available translations of the questionnaire directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.


Original language(s)

  • English for the USA


The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.


Mandarin for China
Spanish for the USA

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.


Conditions to implement in electronic applications

Please refer to the "Contact and conditions of use" tab

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us